Soleno Therapeutics (SLNO) vs. ICU Medical (ICUI) Head to Head Comparison

Soleno Therapeutics (NASDAQ: SLNO) and ICU Medical (NASDAQ:ICUI) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, valuation, profitability, institutional ownership, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Soleno Therapeutics and ICU Medical, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Soleno Therapeutics 0 0 1 0 3.00
ICU Medical 0 2 1 0 2.33

Soleno Therapeutics currently has a consensus target price of $4.00, indicating a potential upside of 142.42%. Given Soleno Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Soleno Therapeutics is more favorable than ICU Medical.

Institutional & Insider Ownership

30.4% of Soleno Therapeutics shares are owned by institutional investors. Comparatively, 75.5% of ICU Medical shares are owned by institutional investors. 69.8% of Soleno Therapeutics shares are owned by company insiders. Comparatively, 13.6% of ICU Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Soleno Therapeutics and ICU Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Soleno Therapeutics -1,389.76% -54.11% -46.95%
ICU Medical 2.79% 4.81% 3.77%

Risk & Volatility

Soleno Therapeutics has a beta of 5.52, indicating that its stock price is 452% more volatile than the S&P 500. Comparatively, ICU Medical has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500.

Valuation & Earnings

This table compares Soleno Therapeutics and ICU Medical’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Soleno Therapeutics $1.45 million 21.89 -$12.06 million ($1.60) -1.03
ICU Medical $379.37 million 11.95 $63.08 million $1.54 146.23

ICU Medical has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than ICU Medical, indicating that it is currently the more affordable of the two stocks.

Summary

ICU Medical beats Soleno Therapeutics on 8 of the 13 factors compared between the two stocks.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc., formerly Capnia, Inc., is a healthcare company that develops and commercializes neonatology devices and diagnostics. The Company also has a therapeutics platform based on its proprietary technology for precision metering of gas flow. The Company offers products, such as CoSense end-tidal carbon monoxide (ETCO) Monitor, NeoPIP Infant Resuscitator and Accessories, and Serenz Nasal Relief. The Company has developed the CoSense End-Tidal Carbon Monoxide Monitor that measures ETCO for the detection of dangerous hemolysis rates. The Infant Solutions product line, including the NeoPIP Infant Resuscitator Unit and accessories, is designed for controlled and accurate resuscitation of neonates and infants in the clinical environment. Serenz Nasal Relief is a hand-held nasal irrigator that uses carbon dioxide (CO2) gas to wash the nasal passages.

ICU Medical Company Profile

ICU Medical, Inc. is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems. The primary critical care products it manufactures are Hemodynamic Monitoring Systems, SafeSet Closed Blood Sampling and Conservation System, Transpac Consumable Blood Pressure Transducers and Other Critical Care Products. The primary oncology products it manufactures are ChemoLock Needlefree CSTD, ChemoClave Needlefree CSTD and Diana Hazardous Drug Compounding System. As of December 31, 2016, its products were used in acute care hospitals and ambulatory clinics in more than 65 countries throughout the world.

Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply